Retatrutide keeps making headlines because of how much weight trial participants lose on it — but headlines are not the same as a licence. As of today, retatrutide has no marketing authorisation anywhere in the world, which means no UK clinician, NHS or private, can legally prescribe it. This guide sets out where the trial programme actually stands, how a medicine like this gets approved in the UK, and what a realistic timeline looks like.
Where the phase 3 programme stands
Retatrutide is being developed by Eli Lilly, the same company behind Mounjaro (tirzepatide). It is being tested in a set of phase 3 trials known as the TRIUMPH programme, covering obesity, obesity with type 2 diabetes, cardiovascular risk, and knee osteoarthritis linked to excess weight.
Through 2026, Lilly has reported a run of positive results from this programme. Earlier trials showed substantial average weight loss over roughly one to two years of treatment, in the same range that first drew comparisons with bariatric surgery. A separate TRIUMPH trial looked specifically at people with knee osteoarthritis linked to excess weight, reporting improvements in both weight and joint pain. In July 2026, Lilly announced positive topline results from two further pivotal trials in people with obesity and serious complications, including type 2 diabetes and established cardiovascular disease. Lilly has said the clinical data package needed to support regulatory submissions for obesity, obstructive sleep apnoea and knee osteoarthritis pain is now essentially complete, with the full TRIUMPH programme expected to finish reporting during 2026.
It's worth being clear about what "positive results" means at this stage. It means the trials met their pre-specified goals — the medicine outperformed the comparison arm on weight loss and the safety data looked broadly consistent with the wider GLP-1 class. It does not mean a regulator has reviewed that data yet, and it doesn't mean every question has been answered. Regulators look for things a topline press release doesn't cover in detail: how side effects behaved in specific groups, whether manufacturing can be scaled reliably, and how the product information should read for prescribers and patients.
Finishing phase 3 is a major milestone, but it is the halfway point of getting a medicine to patients, not the finish line. What happens next is a regulatory process that has its own pace, and it runs separately in every country.
How MHRA approval works
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK's medicines regulator. For a new medicine to be prescribed anywhere in the UK — privately or on the NHS — the manufacturer must first submit a marketing authorisation application, and the MHRA must assess it and grant a licence.
That assessment covers the full trial data package: efficacy across the study population, the safety profile (including rarer or longer-term effects that only show up with enough patients and follow-up time), manufacturing quality, and the proposed product information. Since the UK left the EU's centralised licensing system, the MHRA runs its own process, though it can use routes such as the International Recognition Procedure, which lets it draw on an assessment already completed by a trusted regulator elsewhere (for example the US Food and Drug Administration) to work more efficiently — this doesn't skip the UK review, but it can shorten it.
A recent, directly comparable example is Foundayo (orforglipron), Lilly's once-daily GLP-1 tablet: it was approved in the US in April 2026, and the MHRA granted its UK licence around four months later, in August 2026 — the first approval anywhere in Europe. Our guide to Foundayo's UK approval covers what that process looked like in practice. Retatrutide's own UK timeline hasn't been announced, but that precedent gives a sense of the gap that can exist between a first global approval and a UK licence, once a full submission is made.
There's also the Innovative Licensing and Access Pathway (ILAP), a route the MHRA offers for medicines it judges to be a priority — for conditions with high unmet need, or where a new treatment could offer a meaningful advance. Whether retatrutide would be accepted onto a priority route, and whether that would meaningfully change its timeline, isn't something that can be predicted from the outside. What's certain is that no UK submission can happen before the trial programme and its full data package are finished.
What NICE appraisal would mean
An MHRA licence only settles whether a medicine can be prescribed at all — it doesn't decide whether the NHS pays for it. That's a separate step, run by the National Institute for Health and Care Excellence (NICE), which appraises newly licensed medicines for clinical and cost-effectiveness before recommending (or not recommending) NHS funding.
This appraisal only starts once a medicine has its MHRA licence, and it typically takes many months to complete, sometimes over a year, especially for medicines expected to be prescribed to very large numbers of people — which a weight-loss injection almost certainly would be. Mounjaro and Wegovy both went through this staged process: licensed first, then appraised, then rolled out on the NHS gradually and with eligibility criteria, well after private prescribing had already started. Private prescribing needs only an MHRA licence, so if retatrutide is eventually approved, private access is likely to arrive well before any NHS decision.
Realistic expectations
Put the pieces together and the honest picture is: retatrutide is further along than it has ever been, but every step from here still has to happen in sequence, and none of it has started for the UK yet. Lilly has indicated it plans to submit its US regulatory filing in the first quarter of 2027, once the full data package is ready. Regulatory review of a filing this size typically takes the best part of a year in any jurisdiction, even under a priority process. A UK submission and MHRA assessment would follow — potentially informed by an international recognition route, as with Foundayo, but not confirmed for retatrutide at this stage.
On the timeline Lilly itself has described, private UK prescribing is not realistic before 2027 at the very earliest, and could easily be later — regulatory processes routinely take longer than the optimistic case, whether because a regulator asks follow-up questions, requests more data on a specific subgroup, or needs to inspect manufacturing sites before granting a licence. Any NHS availability, via NICE, would sit further behind that again. Anyone telling you a firm date, or offering to sell you retatrutide before any of this has happened, is not describing a legitimate UK pathway — our guide on where you can get retatrutide in the UK today explains why those routes are unlawful and unverified, and what the risks are.
Licensed options meanwhile
None of this means UK patients have nothing to work with now. Mounjaro (tirzepatide) and Wegovy (semaglutide) are both MHRA-licensed weight-management injections available through a clinical consultation, private or NHS-funded where eligibility criteria are met. Foundayo (orforglipron), the first once-daily GLP-1 tablet, gained its UK licence in August 2026 and is starting to become available too. If you want to understand how retatrutide compares with these mechanistically, our guide to what retatrutide is and how it works sets out the differences.
The right choice between licensed options depends on your health history, BMI, other medicines and preferences — not on which medicine has the highest headline number in a trial. A UK-registered clinician can talk you through what's actually available to you today, and flag when that changes.